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a b s t r a c t 
Electrochemical biosensors for the detection of vital biomarkers is a well-established technology that utilises a 
transducer and recognition element in tandem to determine the presence of an analyte. There is growing inter- 
est in using Molecularly Imprinted Polymers (MIPs) as recognition elements in a wide range of sensing devices 
due to their economic viability and scalability. The inherent properties of polymer platforms, alongside the vast 
array of monomeric options, synthetic routes and incorporation strategies allow for the production of a mul- 
titude of sensitive and selective recognition elements that have significant advantages over classically utilised 
biological entities. MIPs exhibit superior chemical and thermal stability offering a wider variety of immobiliza- 
tion/incorporation strategies, virtually unlimited ambient shelf-life and a longer product lifetime, whilst the vast 
array of monomers available offer flexibility to their synthesis. Even though some sensor platforms have been 
reported for the detection of vital biomarkers, the use of MIPs has a number of challenges and drawbacks that 
need to be overcome in order to produce sensing platforms with the required sensitivity and specificity for clini- 
cal use. In this review, we will provide an overview of the reasoning behind using MIPs as recognition elements 
in electrochemical biosensors for vital biomarkers, discuss the problems synergizing MIPs and electrochemical 
read-out strategies and offer insights into the future perspectives of this promising and innovative technology. 
1. Scope of review 
The development of electrochemical biosensors is an extremely pop- 
ular, ever growing and diverse area of research, with over 2000 research 
papers published in 2019 alone, representing a growth of over 200% 
compared to where the field was in 2003 (see Fig. 1 ) [1] . Electrochemi- 
cal biosensing for clinical biomarker analysis in-particular has received 
significant attention due to the rapid, low-cost and portable nature of 
electrochemical sensing. The rapid detection of clinical biomarkers for 
diagnosis and disease monitoring is particularly important in many clin- 
ical fields such as cancer, sepsis and cardiovascular disease (CVD) [ 2 , 
3 ], with a wide body of evidence demonstrating improved patient out- 
comes following early diagnosis [4–12] . Current testing approaches for 
the biomarkers related to these diseases traditionally utilise interactions 
between antibodies and antigens, with turnaround times ranging from 
hours to days, which can, in some cases, depending on the test, de- 
lay treatment and, potentially, negatively impact outcomes. Molecularly 
Imprinted Polymers (MIPs) are recognition elements that can be tailor- 
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made synthetically to match a biomarker target. Research into the use of 
MIPs for biosensors is rapidly expanding ( Fig. 1 A), due to their superior 
chemical and thermal stability, versatility and low-cost of production 
compared to their conventional biological counterparts [13] . However, 
imprinting for the detection of proteins has been one of the most difficult 
areas in development and there are significant challenges that must be 
overcome to match the specificity and sensitivity of current technology 
and achieve their widespread use as a clinical diagnostics tool [14] . In 
this review, we highlight the work published in the area of developing 
electrochemical MIP biosensors for clinical biomarkers, critically anal- 
yse the challenges that are faced and present our opinion on potential 
future developments. 
1.1. Importance of current methods for clinical biomarker detection 
Cardiovascular disease (CVD), cancer and sepsis are all classified as 
leading causes of death globally, with CVD ranking as the number one 
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Fig. 1. A) Number of publications and number of citations per year for Molecularly Imprinted Polymer Biosensors based on results search and citation report for 
“Molecularly Imprinted Polymers ” and “Biosensor ” on Web of Science [1] conducted on 04/06/2020. B) Plot of the number of publications and number of citations 
per year for Electrochemical Biosensors based on results search and citation report for “Electrochemical ” and “Biosensor ” on Web of Science [1] conducted on 
04/06/2020. 
cause [3] . CVD is responsible for an estimated 17.9 million deaths an- 
nually worldwide, with four out of every five CVD related deaths being 
a direct result of heart attacks (acute myocardial infarction) and strokes 
[15] . In the UK, it affects around 7 million people every year and has 
been reported to cost the NHS approximately £7 billion (GBP) to treat 
annually [16] . Collectively, cancers are the second leading cause of 
death globally, responsible for an estimated 9.6 million deaths (1 in 6) 
globally in 2018 [17] . There is a vast array of different cancers, requiring 
different biomarkers for some aspects of their diagnosis and monitoring. 
For colorectal and breast cancer, the cost to the NHS of treatment is sig- 
nificantly reduced with earlier diagnosis (stages 1 and 2), highlighting 
the demand for rapid point-of-care testing (POCT) to aid with prompt 
diagnosis and treatment [18] . The United Nations World Health As- 
sembly has recognised sepsis as a global health priority. More than 19 
million sepsis cases and 6 million sepsis-related deaths are estimated to 
occur annually. In the UK, the annual number of admissions (77,996) 
and recorded deaths (15,851) related to sepsis has dramatically risen 
in recent years; a 41% and 38% rise between 2015 and 2017 respec- 
tively [2] . The condition is reported to cost the NHS in England approx- 
imately £2 billion annually [19] . It has been reported that over 34% of 
Intensive Care Unit (ICU) patients develop sepsis at some point during 
their stay and 27% of patients with sepsis die, rising to over 50% in pa- 
tients with septic shock [20] . Again, the importance of rapid diagnosis 
is clearly demonstrated by evidence highlighting high mortality rates 
in the absence of prompt treatment; indeed, it has been reported that 
for every hour that sepsis is not identified and treatment is not initi- 
ated, there is a 7.6% reduction in survival rate [21] . Sepsis and cardiac 
dysfunction can be directly linked through a condition known as Sepsis- 
Induced Cardiomyopathy (S-IC) in which the widespread inflammation 
occurring during sepsis negatively affects cardiovascular performance. 
Approximately 50% of patients with sepsis develop S-IC [22] , and this is 
associated with a significantly increased mortality to that of sepsis with- 
out this complication. Therefore, strategies to improve the early iden- 
tification of sepsis and its complications may reduce the severity and 
economic burden of the condition. Indeed, it is estimated that 11,000 
lives and £160 million could be saved every year through improved di- 
agnosis and treatment [19] . 
Prior to the outbreak of SARS-CoV-2 (COVID-19), the POCT market 
was expected to grow in the US to $36.96 billion in 2021 corresponding 
to a compound annual growth rate (CAGR) of 9.8% [23] . This aligns 
well with the reported projected CAGR for electrochemical biosensors 
of 9.7% between 2016 and 2022; with a market value of approximately 
$33 billion by 2027 [24] . Electrochemical immunoassays are the most 
commonly reported form of electrochemical biosensors for detecting 
clinical biomarkers. Classically, this involves the use of specific anti- 
bodies as a recognition element in conjunction with an electrode acting 
as a transducer. The binding phenomena between an antibody and anti- 
gen can then be readily detected through various electrochemical tech- 
niques. Numerous reports of these biosensors have been made for MI, 
cancer and sepsis utilising a variety of electrode materials and designs 
[25–32] . However, many of these suffer in terms of sensitivity, selectiv- 
ity or reproducibility due to common drawbacks with this methodology 
such as the quality of the purchased antibodies, the reliability of the 
immobilisation methodologies, the orientation of the antibodies on the 
transducer, difficulties producing results in biological matrices and the 
lifetime and storage of produced devices [ 33 , 34 ]. Many of these chal- 
lenges come directly from the use of antibodies; as such, there has been 
a focus on replacing these with synthetic recognition elements called 
Molecularly Imprinted Polymers (MIPs). These polymers offer many pos- 
sible advantages over the use of biological recognition elements as they 
offer superior chemical and temperature stability, the ability to tailor 
the synthesis to the target molecule and allow for cheaper production 
[ 35 , 36 ]. 
2. Molecularly imprinted polymers 
The first English report of Molecularly Imprinted Polymers (MIPs) 
was produced in 1949 by Dickey, who introduced some of the key con- 
cepts used in MIP development today, such as identification of the target 
molecule as a “template ” [37] . The more commonly seen non-covalent 
imprinting that is predominantly used in current research was first in- 
troduced by the group of Mosbach in the 1980 ′ s [38–40] . The general 
description of MIPs is that of a polymeric matrix with distributed bind- 
ing cavities that are specific for the size, shape and functionalities of 
the imprinted template. They are generally formed through a generic 
sequence of events, as shown schematically within Fig. 2: 1) the incu- 
bation of monomers with either a template molecule, dummy template 
or an epitope, allowing for non-covalent interactions to form between 
the functional monomers and the template and for them to stabilise; 2) 
the polymerisation of the monomers to form a polymer around the tem- 
plate, effectively trapping it in the polymeric matrix; 3) the removal or 
extraction of the template from the polymer to leave specific binding 
cavities of the same size and shape for that template. 
The interactions between monomers and templates can be studied 
prior to synthesis through computational modelling, which can dic- 
tate or be dictated by synthesis choice [41] . How the polymerisation 
procedure is accomplished can vary greatly between the vast array of 
synthetic routes for MIP formation, such as UV polymerisation [42] , 
thermal polymerisation [43] , Reversible Addition–Fragmentation chain 
Transfer (RAFT) polymerisation [44] and solid-phase synthesis [45] to 
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Fig. 2. Schematic of the general production methodology for a Molecularly Imprinted Polymer. A pre-polymerisation mixture allows for the non-covalent interactions 
to stabilise between the template and the functional monomers. The polymerisation process then freezes the template inside the polymer matrix. The template is 
then removed from the polymer leaving a binding cavity of complementary size, shape and functionality to the target. When the target is introduced it will bind 
back inside the cavity. 
name a few; more detailed explanations of these processes can be found 
in the following reviews: [46–49] . However, traditional bulk imprinting 
has proved challenging for proteins due to their reduced mass transfer, 
permanent entrapment in the polymer matrix, poor structural integrity 
of the polymer, restricted synthetic routes especially in solvent selection 
and the heterogeneity of binding sites [50–52] . All the different routes 
for MIP synthesis can lead to significant differences in the properties 
and morphologies of the final product. This can be advantageous for 
tailoring production but has led to a vast majority of systems struggling 
to achieve the synergy, selectivity and sensitivity needed to perform at 
the required standards in sensor platforms. 
The majority of reports utilising a combination of MIPs and electro- 
chemical detection use electropolymerization as their chosen method of 
MIP formation [ 53 , 54 ]. This synergises well with the overall platform 
due to the possibility of producing both conductive and non-conductive 
polymers (depending on the desired platform and electrochemical detec- 
tion method) and the direct formation of the MIP layer on the surface of 
the transducer, effectively removing a time-consuming immobilisation 
step. This methodology is based on the formation of polymers through 
the application of potential, causing an oxidation or reduction in the 
monomers and has been applied to the detection of a range of biolog- 
ical targets [55] . Although convenient, the formation of MIPs through 
electropolymerization has significant challenges to overcome such as 
the more limited supply of suitable monomers, the homogeneity of the 
binding sites produced and the scalability of the process. Other methods 
of synthesis that produced superior performing MIPs typically struggle 
with reproducibility of immobilization techniques or synergising with 
the read-out technique; however, some excellent examples of MIP sen- 
sors have been achieved for biological targets using dip-coating [ 56 , 
57 ], screen-printing [ 43 , 58 ] or a sol-gel approach [59–61] . In order 
to achieve the levels of detection and reliability required for a success- 
ful sensor for clinical biomarkers, careful optimisation of the synthesis, 
template removal and detection parameters must be carefully applied. 
Throughout this review, we highlight some of the recent reports of elec- 
trochemical MIP sensors for clinically relevant biomarkers and discuss 
how they achieved their goal or how they could be improved in future 
work. 
3. Biomarker detection 
3.1. Acute myocardial infarction (AMI) 
AMI, commonly known as a heart attack, occurs when there is a de- 
crease or stop in the flow of blood to a part of the heart that leads to 
myocyte necrosis [62] . In 1999, the Joint European Society of Cardiol- 
ogy/American College of Cardiology Committee released a new defini- 
tion for AMI that emphasised the importance of biomarkers in the di- 
agnosis, introducing cardiac troponins (cTn) as the gold standard [63] . 
This was updated in 2012 and 2018, both times emphasising the role 
of cTn levels in the diagnosis of AMI [ 64 , 65 ]. Cardiac troponins T and 
I (cTnT and cTnI) are encoded by different genes, which makes them 
immunologically distinct [66] . Both have been reported as specific and 
sensitive biomarkers for AMI and superior to creatinine kinase-MB and 
myoglobin as indicators for myocardial necrosis. Some novel emerging 
biomarkers include heart-fatty acid binding protein (h-FABP), B-type na- 
triuretic peptide (BNP), ischaemia-modified albumin (IMA), pregnancy- 
associated plasma protein A (PAPP-A), copeptin and growth differen- 
tiation factor-15 (GDF-15) [67] . In the UK, the National Institute for 
Health and Care Excellence (NICE) committee, recommends two tro- 
ponin assays (Roche Elecsys R ○ measures troponin-T levels and Abbott’s 
Architect STAT Troponin-I assay) for the rule-out of AMI in patients with 
suspected heart attack. These tests measure troponin levels in serum at 
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Table 1 
Summary of MIP based electrochemical sensors for cardiac biomarkers, highlighting the polymer used, electroanalytical method of 
detection, linear range and limit of detection. 
Target MIP Electrode Material Detection Method Linear Range Limit of Detection Reference 
cTnT a o -PD c Au m CV r 0.009–0.8 ng mL − 1 9 pg mL − 1 [75] 
cTnT a PANI d SPCE n DPV s 0.02–0.09 ng mL − 1 0.008 ng mL − 1 [78] 
cTnT a PANI d SPCE n DPV s 0.1–8.0 pg mL − 1 0.04 pg mL − 1 [80] 
cTnT a AAM e MWCNTs o Potentiometric – 0.16 μg mL − 1 [70] 
cTnT a PPy f SPCE n DPV s 0.01–0.1 ng mL − 1 0.006 ng mL − 1 [79] 
cTnI b PPy f GCE p DPV s 0.01– 5.0 ng mL -1 0.0005 ng mL − 1 [83] 
cTnI b o -AP g GCE p DPV s 0.05–5 nM 0.027 nM [82] 
cTnI b MB h GCE p DPV s 0.5–3.3 × 10 5 pM 1.04 pM [85] 
cTnI b MAA i GCE p DPV s 0.005–60 ng cm − 3 0.0008 ng cm − 3 [84] 
Myoglobin o -AP g Au-SPE q SWV t 0.8 μg mL − 1 [93] 
Myoglobin IL j GCE p CV r 0.06–6 μM 9.7 nM [96] 
Myoglobin AAM e Au-SPE q EIS u 0.852–4.26 μg mL − 1 2.25 μg mL − 1 [92] 
Myoglobin MMA i Au m DPV s 1 x 10 –10 –0.1 mg l − 1 1.1 x 10 –11 mg L − 1 [97] 
Myoglobin Phenol Au-SPE q DPV s 0.001 ng mL − 1 –100 μg mL − 1 2.3 pg mL − 1 [90] 
Myoglobin o -PD c SPCE n DPV s 1 nM–1 μM 0.5 nM [98] 
Myoglobin SSA k /AEHM l Au-SPE q SWV t – 0.79 μg mL − 1 [91] 
Myoglobin AAM e Au-SPE q EIS u 1–20,000 ng mL − 1 0.83 ng mL − 1 [89] 
a cardiac troponin T, b cardiac troponin I, c o-phenylenediamine, d polyaniline, e acrylamide, f polypyrrole, g o-aminophenol, h methylene 
blue, i methacrylic acid, j ionic liquid, k 4-styrenesulfonic acid, l 2-aminoethyl methacrylate hydrochloride, m gold, n screen-printed 
carbon electrode, o multi-walled carbon nanotubes, p glassy carbon electrode, q gold screen-printed electrode, r cyclic voltammetry, s 
differential pulse voltammetry, t square wave voltammetry, u electrochemical impedance spectroscopy. 
various time points and measured high levels, along with a typical rise 
and fall pattern of troponin, are strongly associated with cardiac events. 
However, there are significant limitations associated with these assays 
which include high cost and long measurement time due to the assay re- 
quiring a lab environment, which can have a negative impact on patient 
outcome since this is strongly linked to time for diagnosis. 
A comparison between thirteen commercial troponin assays showed 
good correlation between the methods, while correlation between cTnI 
and cTnT levels varied substantially which can lead to issues with stan- 
dardization of measurements [68] . 
To avoid the issues around turn-around time, other European coun- 
tries have adopted new platforms such as the Siemans Atellica R ○ So- 
lution, which received FDA clearance in 2018. This system combines 
immunoassays and clinical chemistry analysers to reduce measurement 
times. Although measurement times have been improved, a common 
problem throughout clinical use is the slow turnaround time for results, 
stemming from sample procurement, transport to labs, and subsequent 
analysis, putting a significant burden on already overstretched clinical 
staff. In addition, the demand for troponin tests has rapidly increased, 
as it has been identified as a prognostic marker for many conditions, in- 
cluding COVID-19 progression [69] . This has ignited the interest in suit- 
able POC platforms for detection of cardiac troponins and myoglobin, 
summarised in Table 1 , which will overcome many of these current lim- 
itations. 
The first reported MIP electrochemical biosensors in this area was 
published in 2011 by Moreira et al. [70] who produced the MIP re- 
ceptors, specific for cTnT, onto the surface of multi-walled carbon nan- 
otubes (MWCNT). This reportedly utilised the key characteristics of 
MWCNT such as their high strength, stability, lack of swelling and large 
active surface areas [71] . In conjunction with MIPs this method has the 
potential to produce stable potentiometric sensor platforms with good 
compatibility between the transducer, modification and recognition el- 
ement [72] . However, the sensor platform did not reach the required 
relevant detection levels of cTnT (1–5 ng/L) [73] . This is likely due 
to the lack of homogeneity of the MIP binding sites, which is a com- 
mon trait among MIP platforms produced using this synthesis method- 
ology. The most commonly utilised electrochemical detection method- 
ology found in the literature is the suppression of redox probes, such as 
ferri/ferrocyanide through binding phenomena. This is demonstrated 
by Kariman et al. [ 74 , 75 ] who produced a sensor platform specific for 
cTnT through the electropolymerisation of o -phenylenediamine (o-PD). 
This is becoming a more popular choice of monomer for the formation of 
electropolymerised MIPs due to the excellent stability of the produced 
film and mild conditions required for formation [ 76 , 77 ]. The sensor 
performed well in buffered solutions, producing a LOD of 9 pg mL -1 
and working range of 0.009–0.8 ng mL -1 ; however, it struggled with 
increased noise on the signal when measuring in more complex me- 
dia. There have been attempts to improve the response of MIP systems 
towards cTnT utilising this redox probe by incorporating nanomateri- 
als into the sensor design, such as reduced graphene oxide [ 78 , 79 ]. 
This modification is achieved through drop-casting and produced re- 
producible results in diluted serum. However, the incorporation of this 
nanomaterial adds extra manufacturing steps into sensor production, 
whilst still requiring sample pre-treatment for measurement. More re- 
cently, Phonklam et al. [80] utilised electropolymerisation to produce 
polyaniline (PANI) MIPs on MWCNT with polymethylene blue (PMB) 
for cTnT, ( Fig. 3 A and B). In this way, the redox probe was immobi- 
lized onto the surface of the electrode instead of being free in solution, 
which increases the suitability for a Point-of-Care (POC) system. PANI 
was chosen as the imprinting polymer as it is possible to finely tune the 
polymer layer thickness through controlling the parameters of deposi- 
tion and charge passed [53] . 
Although PANI offers some excellent properties such as its electri- 
cal conductivity, stability, ease of deposition and low-cost; the structure 
of the monomer is simplistic and only offers a single protonated amine 
group that can form non-covalent interactions with the target molecule, 
such as the carboxylic acid functionality on a protein [81] . This will 
limit the amount of highly specific binding sites produced in the matrix 
and lead to questions about selectivity and reproducibility. However, in 
this work, the selectivity studies show promising results with little inter- 
ference from proteins such as cTnI. The LOD obtained for cTnT in this 
work of 0.04 pg mL -1 is well below the required normal physiological 
range required, with the linear working range of the sensor reported as 
0.1–8.0 pg mL -1 . This raises questions about real-world applications for 
the technology, as this will obviously require sample pre-treatment for 
it to be in the correct concentration range. 
The amount of literature published on the detection of cTnI is more 
limited than that for cTnT. In general, the sensors developed in this area 
again rely on the use of the ferri/ferrocyanide redox probe described 
above, in conjunction with the MIP immobilised onto the electrode sur- 
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Fig. 3. A) Schematic illustration of the fabrication of a MIP based sensors for cTnT. Reproduced/adapted with permission from ref [80] . Copyright 2020 Elsevier. 
B) SEM images of MWCNT at different stages of sensor production with corresponding cyclic voltammograms. Reproduced/adapted with permission from ref [80] . 
Copyright 2020 Elsevier. C) DPV curves for the detection of cTnT with a MIP and NIP sensor combined with their corresponding sensing plots. Reproduced/adapted 
with permission from ref [74] . Copyright 2014 Elsevier. 
face. There are examples of solutions relying solely on the MIP and an 
electrode [82] , with the use of a single additive such as Boron Nitride 
Quantum Dots (BNQDs) [83] or with multiple added nanomaterials in 
a layer-by-layer fashion [84] . An interesting new methodology, that is 
receiving more recognition recently is the combination of MIPs with 
aptamers to form a hybrid sensing platform with dual recognition ca- 
pabilities [85] . Aptamers are artificial nucleic acids or peptides that are 
designed for a specific target. When used in combination with MIPs they 
can help overcome the limitations that using solely non-covalent bond- 
ing presents [86–88] . In this way, the selectivity and specificity of ap- 
tamers are combined with the functionality, size and shape recognition 
of MIPs. Mokhtari et al. [85] bound aptamers specific for cTnI onto the 
surface of ZnO nanoparticles (ZnONPs), then immobilized these onto the 
surface of a GCE, Fig. 4 A. Once the cTnI was bound to the aptamers, a 
layer of polymethylene blue (PMB) was electropolymerised around the 
aptamers/target complex. Following target removal, a hybrid recogni- 
tion layer was left on the surface of the electrode combining a PMB MIP 
and aptamers. The binding of the target cTnI to the aptamers/MIP layer 
hinders the electron transfer from the PMB layer to the electrode surface 
producing a measurable decrease in the differential pulse voltammo- 
grams. In this way, the redox probe is encased in the sensing platform, 
and does not require an external solution change. This methodology 
offered a significant improvement in linear range over other reported 
systems from 0.5 to 3.3 × 10 5 pM, with a 1.04 pM LOD, which both 
meet the required LOD and biologically relevant analytical range for 
use. The issues with the system remain the transition from lab based 
sensor device to mass producible POCT, which is a common trait for 
MIP based electrochemical sensors utilising electropolymerisation as a 
key production method. 
There is a more varied range of literature for the production and 
detection methods used for MIP based sensors targeting myoglobin. 
This is most likely due to the significant difference in purchase cost be- 
tween the cardiac troponins and myoglobin, allowing for significantly 
more optimization of MIP composition at a lower cost per experiment. 
There are still several examples that utilise the ferri/ferrocyanide redox 
probe for their detection; relying on an inhibition in signal for either 
Differential-Pulse Voltammetry (DPV) [90] , Square-wave Voltammetry 
(SWV) [91] or Electrochemical Impedance Spectroscopy (EIS) [ 92 , 93 ]. 
EIS is a commonly explored detection strategy in conjunction with MIPs 
as it allows the user to monitor surface changes and complex binding 
events [ 94 , 95 ]. The characteristic semi-circular plots, seen in Fig. 4 B, 
represent the electron transport resistance or charge transfer resistance 
( R CT ). In the work presented by Karami et al. [89] , the binding of myo- 
globin (or PSA) to the acrylamide based dual MIP sensor inhibits the 
transfer of charge through the interface to the electrode surface result- 
ing in a measurable increase in the R CT . This platform utilised photo- 
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Fig. 4. A) Schematic representation of the aptamer/MIP receptor formation onto ZnONPs for cTnI detection. Reproduced/adapted with permission from ref [85] . 
Copyright 2020 Elsevier. B) EIS data for the MIP electrodes for incubation with myoglobin. Reproduced/adapted with permission from ref [89] . Copyright 2020 
Elsevier. C) Comparison between the DPV response for the NIP and MIP for myoglobin. Reproduced/adapted with permission from ref [90] . Copyright 2017 Elsevier. 
chemical polymerization with acrylamide as the functional monomer 
and N,N’-methylenebisacrylamide as the crosslinker monomer. Using 
this polymerization method produces a non-conductive polymer which 
will inherently hinder using electrochemical detection methods such as 
DPV or CV; whereas EIS offers a way around this. This sensor produced 
a low LOD of 5.4 pg mL -1 and wide working linear range of 1–20,000 
pg mL -1 . 
Although, the use of non-conductive MIPs with an electrochemi- 
cal detection strategy seems counter intuitive, Ribiero et al. [90] have 
shown it is possible to produce a functioning sensor for the detec- 
tion of myoglobin using DPV. They utilise the non-conductive polymer 
polyphenol, which as well as being known for electrode fouling, can 
be used to as recognition elements due to its ability to interact with 
molecules through 𝜋- 𝜋 stacking. The issue with systems that use this 
method are the small linear ranges that can be achieved due to the 
small redox signal obtainable through a non-conductive polymer. Us- 
ing EIS for a system like this could provide a wider working range to 
improve the system. 
In terms of cardiac biomarker sensing using electrochemical MIP sen- 
sors, there is a plethora of examples using DPV in conjunction with a free 
redox probe; however, there are drawbacks when trying to convert lab- 
oratory work into real world POCTs. In addition, a balance needs to be 
struck between enhancing signals with nanomaterials and layer modi- 
fications and actual mass production capabilities. This includes the use 
of electropolymerisation and its suitability for mass producing POCTs. 
3.2. Sepsis 
Sepsis is a life-threatening condition caused by a dysregulated host 
response to infection. The infection is the instigator, while the host’s 
immune system is responsible for the widespread organ damage charac- 
teristic of sepsis. If sepsis is not identified and treated rapidly, it will 
lead to multi-organ failure and death. While the definition of sepsis 
keeps on evolving [99] , clinical assessment based on physiological and 
molecular biomarkers, plus the identification of blood stream infection 
(BSI) are crucial for early diagnosis and targeted management, yet these 
involve prolonged laboratory procedures (for the biomarkers) and the 
in-vitro detection or proliferation of bacteria, virus or other organisms 
which can take up to 72 h, or longer. Current UK guidelines for the early 
recognition and management of sepsis therefore include a combination 
of clinical judgement, observation of key physiological parameters via 
screening tools and consideration of patient risk factors and blood in- 
flammatory markers (C-Reactive Protein (CRP), White Blood Cell Count 
(WBC), Procalcitonin (PCT) and others such as lactate and blood cultures 
(BC)). PCT and CRP are FDA approved for the assessment of progres- 
sion of infection to sepsis, for aiding in decisions for antibiotic therapy 
for some patients, and also for the potential de-escalation of antibiotics 
for septic patients if tracked over time [100–102] . A heightened under- 
standing of the inflammatory processes that lead to host tissue damage 
in sepsis has led to the identification of several other biomarkers with a 
high level of specificity to be identified. A hyper-inflammatory cytokine 
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Table 2 
Summary of MIP based electrochemical sensors for sepsis and cancer biomarkers, highlighting the polymer used, electroana- 
lytical method of detection, linear range and limit of detection. 
Target MIP Electrode Material Detection Method Linear Range Limit of Detection Reference 
CRP a AEDP g /DMAA h SPCE n DPV r – 0.04 μg mL -1 [108] 
IL-1 𝛽b EBT i SPCE n EIS s 0.06– 600 nM 1.5 pM [116] 
IL-8 c 3-APBA j Au o CV t 0.1–10 pM 0.04 pM [115] 
lactate 3-APBA j SPCE n EIS s 3–100 mM 1.5 mM [109] 
lactate o -PD k GCE p DPV r 0.1 - nM 0.09 nM [127] 
lactate 3-APBA j SPCE n DPV r 10 –6 –0.1 M 0.22 μM [110] 
CA-15 d o -AP l Au-SPE q DPV r 5–50 U mL − 1 1.5 U mL − 1 [123] 
CA-15 d TB m Au o DPV r 0.1–100 U mL − 1 0.1 U mL − 1 [122] 
HER2-ECD e Phenol Au-SPE q DPV r 10–70 ng mL − 1 1.6 ng mL − 1 [125] 
PSA f Dopamine Au o EIS s 0.1–100 ng mL − 1 1.0 pg mL − 1 [124] 
a c reactive protein, b interleukin-1 𝛽, c interleukin-8, d cancer antigen 15, e human epidermal growth factor receptor – ex- 
tracellular domain, f prostate specific antigen, g 2-acryl amidoethyldihydrogen phosphate, h N-(4-dimethylaminophenyl)- 
acrylamide, i eriochrome black T, j 3-aminophenylboronic acid, k o-phenylenediamine, l o-aminophenol, m toluidine blue, n 
screen-printed carbon electrode, o gold, p glassy carbon electrode, q gold screen-printed electrode, r differential pulse voltam- 
metry, s electrochemical impedance spectroscopy, t cyclic voltammetry. 
response [103] , including production of IL-1 𝛽, IL-6, IL-8 and TNF- 𝛼, as 
well as products of cellular damage ( e.g. High Mobility Group Box 1, 
HMGB1), has widespread effects on multiple organ systems. The ability 
to assess the patient’s inflammatory phase in the clinical setting would 
therefore allow for improved risk stratification and treatment decision 
making. All of this makes the use of immunoassays toward the rapid 
diagnosis of sepsis interesting due to their ability to give results on the 
minute timescale, which would allow for the immediate start of treat- 
ment, potentially improving survival rates. 
The development of biosensors for sepsis has been sparse in com- 
parison to the more widely known diseases such as cancer and my- 
ocardial infarction, and there has been significantly less development 
in terms of MIP based electrochemical sensors, a compilation is pre- 
sented in Table 2 . All sensor platforms developed in the previous section 
for cardiac biomarkers are applicable to the detection of sepsis-induced 
cardiomyopathy (S-IC); however, they will not aid in the diagnosis or 
monitoring of the clinical course of sepsis itself. Currently, from the 
FDA approved markers for the assessment of sepsis there have been MIP 
designs for PCT [104] , CRP [ 105 , 106 ] and lactate [107] . In terms of 
electrochemical MIP based sensor platforms, there is an example for 
CRP [108] . By far the most abundantly studiedare lactate sensors, most 
likely due to the lower cost of the target and multiple applications for a 
sensor of this type, such as in the field of athletic performance. The two 
sensors described in literature that aim predominantly at utilisation this 
both use electropolymerisation of 3-aminophenylboronic acid (3-APBA) 
as their functional monomer for MIP formation, which highlights the im- 
portance of selecting suitable monomers for the application [ 109 , 110 ]. 
Poly(3-APBA) can be formed on the surface of the transducer via oxida- 
tive electropolymerisation [111] with the boronic acid functional groups 
attached to the polymer backbone being free to interact with hydroxyl 
containing compounds [ 112 , 113 ]. 
Zhang et al. [110] focussed on producing a wearable sweat sensor 
for monitoring muscular performance during exercise, however as the 
relevant concentration levels are similar it has potential for use in other 
areas such as septic shock diagnosis [114] . They utilised SPEs as the best 
flexible working electrode material modified with Ag Nanowires (Ag- 
NWs, 120 nm diameter and 15 μm length, Fig. 5 A) due to their excellent 
electrical conductivity and adequate flexibility; the MIPs primarily form 
on the AgNWs due to this enhanced conductivity. The system uses DPV 
of the ferri/ferrocyanide redox couple for its method of detection which 
produces a wide logarithmic linear working of 10 –6 – 0.1 M with a LOD 
of 0.22 μM, Fig. 5 B. This platform shows very promising results, how- 
ever, there are drawbacks with the sensor being mass producible. Screen 
printing lends itself excellently to mass production, but electropolymeri- 
sation of every electrode for 30 cycles at 50 mV s -1 would provide manu- 
facturing challenges; although once production has been completed the 
device can be marketed as ready to use. Other than this, the results pub- 
lished highlight why electrochemical MIP sensor platforms are a signif- 
icant area of interest for POCT, as the sensor showed no degradation in 
performance even after dry storage over 7 months. This explicitly shows 
one of the main advantages that MIPs bring to POCT when compared 
with their biological recognition element counterparts such as antibod- 
ies. 
There have been very few examples of MIP based electrochemical 
sensors for the detection of inflammatory markers. One report for the 
detection of interleukin-8 based on MIPs formed on Fe 3 O 4 nanoparti- 
cles produced a low LOD but very narrow linear working range [115] . 
A more promising novel approach for detecting interleukin-1 𝛽 was re- 
ported by Cardoso et al. [116] The group has pioneered the use of Eri- 
ochrome Black T (EBT) as a functional monomer for electropolymeri- 
sation and the formation of MIPs [117] . It possesses several different 
functional groups that allows for the formation of many non-covalent 
interactions in addition to its highly extended 𝜋 system. In the sensor 
platform for IL-1 𝛽, the SPE is coated with PEDOT/4-aminothiophenol to 
form a linking group between the MIP and the transducer. When formed, 
the MIP has a significantly negatively charged surface, which in turn 
leads to a higher charge transfer resistance (R CT ) when measured using 
ferri/ferrocyanide redox couple due to electrostatic repulsions [118] . As 
binding of the target occurs, the protein’s heterogeneous charge distri- 
bution lowers the electrostatic repulsion resulting in a measurable de- 
crease in the R CT [119] . This allowed a LOD of 1.5 pM to be obtained 
with a wide linear range of 60 pM to 600 nM showing its suitability for 
the application. However, the triple electropolymerised functionaliza- 
tion of the electrode indicates there would be issues in mass production 
of the device. Additionally, no data has been reported for the lifetime 
of this sensor and it negatively charged MIPs may not be as durable as 
uncharged MIPs. 
3.3. Cancer 
There are a vast array of different types of cancers, the most com- 
mon of which include lung, breast, colorectal, prostate, skin and stom- 
ach [17] . The TNM staging system is a standard method of diagnosing 
and classifying cancer stages, where T denotes the size of a tumour, N 
denotes the lymph node spread and M denotes the presence of absence 
of metastases. This method remains useful for bulk classification but 
the presence and measurement of individual biomarkers can help with 
subdividing classes to aid with monitoring, treatment approaches and 
recovery [120] . There is a vast array of different biomarkers that can 
be associated with different cancer types; For example, Carcinoembry- 
onic Antigen (CEA) and Epidermal Growth Factor Receptor (EGFR) are 
both useful markers in colon cancer, where CEA can aid in monitoring, 
R.D. Crapnell, N.C. Dempsey-Hibbert, M. Peeters et al. Talanta Open 2 (2020) 100018 
Fig. 5. A) SEM images of the screen-printed carbon working electrode, AgNWs 
coated on the electrode and MIPs formed on the AgNWs. Reproduced/adapted 
with permission from ref [110] . Copyright 2020 Elsevier. B) EIS data for the 
functionalization of MIP electrodes and DPV data for incubation with lactate. 
Reproduced/adapted with permission from ref [110] . Copyright 2020 Elsevier. 
while EGFR is clinically used to help select appropriate therapies [120] . 
A summary of some MIP based electrochemical biosensors can be found 
in Table 2 . 
Breast cancer is one of the most commonly diagnosed cancers world- 
wide, with Human Epidermal Growth Factor Receptor 2 (HER2), Can- 
cer Antigen 15–3 (CA 15–3) and CEA being the most widely reported 
biomarkers [121] . This is also the cancer that has received the most re- 
ports of MIP based electrochemical sensors. Two sensor platforms have 
been reported recently for CA 15–3 by Ribeiro et al. [122] and Pacheco 
et al. [123] , which utilise similar methodologies for the analysis. Both 
systems utilise DPV as their electroanalytical technique and produce 
LOD’s and linear working ranges at similar levels. The study by Ribeiro 
does report a wider working range at 0.1–100 U mL -1 and slightly lower 
LOD at 0.1 U mL -1 , Fig. 5 B. As the systems presented both utilise Au 
SPEs, DPV and the ferri/ferrocyanide redox couple, the difference be- 
tween the two is expected to be predominantly due to the choice of 
functional monomer for the MIP. 
Pacheco utilised 2-aminophenol as the functional monomer, which 
produces a non-conductive polymer network. Using a non-conductive 
polymer alongside electroanalytical detection methods will always limit 
the working linear range of a system. In comparison, Ribeiro and 
coworkers utilised Toludine Blue as their functional monomer which 
Fig. 6. A) Schematic representation of the sensor fabrication for the ap- 
tamer/MIP based platform. Reproduced/adapted with permission from ref 
[124] . Copyright 2016 Elsevier. B) DPV data in the presence of 5 mM 
[Fe(CN) 6 
3-/4- with the MIP (A) and NIP (B) along with the associated calibration 
plots (C) and binding isotherms (D). Reproduced/adapted with permission from 
ref [122] . Copyright 2018 Elsevier. 
produces a conductive polymer. To achieve this, they created a self- 
assembled monolayer (SAM) with a toluidine blue tail group to act as a 
linker between the polymer and electrode surface. This helps to produce 
the greater working linear range but also adds significantly longer times 
to platform production. In this way, the system reported by Pacheco 
could be fully prepared and ready to use in the same time it took for just 
the SAM to form for the alternative system. Pacheco et al. [125] also re- 
port a similar system for the detection of another breast cancer marker 
(HER2) utilising phenol as their functional monomer. This highlights 
key parameters that need to be considered when developing a sensor 
platform suitable for commercialisation as a POCT; the balance between 
sensitivity, working range and production scalability is vital. 
In terms of biomarkers for other cancers, Jolly et al. [124] reported 
a hybrid MIP/aptamer, Fig. 6 A, sensor (the benefits of these systems are 
discussed earlier) for the detection of prostate specific antigen (PSA). 
Firstly, the aptamer is immobilized onto the gold surface, then the tar- 
get is introduced and bound to the aptamer, followed by MIP formation 
around this complex. The imprinting step here is achieved through elec- 
tropolymerization of dopamine, which binds readily to electrode sur- 
faces [126] . This sensor platform produced a linear response from 100 
pg mL -1 to 100 ng mL -1 which highlights the strength of these hybrid 
devices. 
As we begin to see more of these hybrid designs in sensor plat- 
forms there is a key compromise that must be addressed by researchers; 
namely, the balance between achieving the relevant biological LODs 
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and working ranges and, the methodology of sensor preparation and its 
viability for scalable mass production and cost effectiveness. 
5. Conclusions and future outlook 
The development of electrochemical biosensors that incorporate 
MIPs as their recognition element are gaining popularity in research 
due to the significant benefits that MIPs bring. The ability to tailor a 
production method to a specific target, the excellent chemical and ther- 
mal stabilities, the reduction in the use of animals and the low-cost of 
polymers mean that they are well suited to the application. There are 
several examples of MIP based sensors in recent years that match the 
required LOD and working linear range to be biologically relevant, how- 
ever the majority of these use complicated production methodologies. In 
our opinion the greatest challenge in the development of MIP based sen- 
sors that are used in real world applications, be that clinical POCT or as 
home monitoring/diagnosis kits, is the optimization of production meth- 
ods. This means developing methods that can produce sensor platforms 
that reach the biologically relevant detection levels, whilst also being a 
scalable mass production methodology. Overcoming the drawbacks of 
electropolymerisation (mass production difficulties), bulk polymeriza- 
tion (heterogeneous binding sites) and many other synthetic methods 
(poor synergy with electrochemical detection) are all key challenges to 
address. Given the significant advantages that MIPs offer to sensor plat- 
forms, we expect this area of research to be of expanding interest in the 
future. 
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